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Synthesis of optically active 1-(1-phenylethyl)imidazoles eerived
from 1-phenylethylamine
Abstract
The three-component reaction of (R)- or (S)-1-phenylethylamine (6), formaldehyde, and an
-(hydroxyimino) ketone 5, i.e., 3-(hydroxyimino)butan-2-one (5a) or
2-(hydroxyimino)-1,2-diphenylethanone (5b), yields the corresponding enantiomerically pure
1-(1-phenylethyl)-1H-imidazole 3-oxide 7 in high yield (Schemes 2 and 3). The reactions are carried out
either in MeOH or in AcOH. Smooth transformations of the N-oxides into optically active
1-(1-phenylethyl)-1H-imidazoles 10 and 2,3-dihydro-1-(1-phenylethyl)-1H-imidazole-2-thiones 11 are
achieved by treatment of 7 with Raney-Ni and 2,2,4,4-tetramethyl-3-thioxocyclobutanone (12),
respectively (Scheme 4).
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1) Presented in preliminary form at the 50th Annual Meeting of the Polish Chemical
Society, Torun, Poland, September 2007.
2The three-component reaction of (R )- or (S )-1-phenylethylamine (6),
formaldehyde, and an α-(hydroxyimino)ketone 5, i.e., diacetylmonooxime (5a) or
benzil monooxime (5b), yields the corresponding enantiomerically pure 1-(1-
phenylethyl)imidazole 3-oxide 7 in high yield (Schemes 2 and 3). The reactions are
carried out either in methanol or in acetic acid. Smooth transformations of the N-oxides
into optically active 1-(1-phenylethyl)imidazoles 10 and 1-(1-phenylethyl)imidazole-
2(3H)-thiones 11 are achieved by treatment of 7 with Raney Ni and 2,2,4,4-tetramethyl-
3-thioxocyclobutanone (12), respectively (Scheme 4).
31. Introduction. – Imidazole derivatives are widely applied as versatile building
blocks for the preparation of more complex molecules [1]. Several compounds
containing the imidazole moiety display relevant biological activities (e.g. [2–5]).
Recently, some new methods for the synthesis of differently substituted imidazoles were
described [6-8]. Furthermore, in a series of papers, 2-unsubstituted imidazole 3-oxides
were shown to be useful starting materials for the preparation of imidazole derivatives
such as imidazole-2-thiones [9], imidazol-2-ones [10], 2-cyanoimidazoles [10], 2-
(perfluoroethyl)imidazoles [11], 2-(dicyanomethylidene)imidazoles [12], as well as the
parent imidazoles [12][13].
Relatively little is known about optically active imidazole derivatives bearing
substituents with stereogenic centers [14]. In the first paper on optically active
imidazole 3-oxides, a three-component reaction with α-(hydroxyimino)ketones,
formaldehyde, and optically active α-amino acids was reported [15]. By using a
modified procedure, we succeeded in the preparation of some optically active imidazole
3-oxides 1 starting with enantiomerically pure β-amino alcohols, e.g. 2 [13] (Scheme 1).
The corresponding formaldimine 3, which is in equilibrium with its trimer 4, reacts with
α-(hydroxyimino)ketones 5 in refluxing EtOH to give 1. Analogous amino components
were exploited in a multi-component reaction with an aldehyde, a diketone, and
ammonia to yield imidazoles with a chiral 2-hydroxyethyl group attached to N(1) [16].
In a very recent paper we reported the synthesis of a new type of optically active bis-
imidazoles by using enantiomerically pure trans-1,2-diaminocyclohexane [17].
Scheme 1
4It is well known that along with trans-1,2-diaminocyclohexane the commercially
available and cheap enantiomerically pure 1-phenylethylamine (α-methylbenzylamine)
is one of the most frequently used chiral amine in organic synthesis (see for example
[18]). The present paper is aimed at the preparation of new optically active imidazole
derivatives based on 1-phenylethylamine2) as the key reagent used in the reaction with
formaldehyde and α-(hydroxyimino)ketones.
2. Results and Discussion. – The three-component reaction carried out with
equimolar amounts of (R)-(+)- and (S)-(–)-1-phenylethylamine (6 ) ,  respectively,
formaldehyde, and diacetylmonooxine (5a) in boiling EtOH gave the expected
imidazole 3-oxide albeit in low yield. Therefore, the alternative method presented in
Scheme 1 was applied. Thus, the amine 6 and formaldehyde reacted in MeOH at room
temperature to yield the corresponding 1,3,5-triazinane of type 4 as an oily product,
which, without purification, was treated with 5a leading to the desired product 7a in
good yield (Scheme 2).
Scheme 2
The spectroscopic data confirm the structure of the product: e.g., the 1H-NMR
spectrum revealed the typical signal of H-C(2) at 8.16 ppm. Furthermore, the presence
of the 1-phenylethyl residue was proved by the doublet of the Me group (1.82 ppm, J =
                                                           
2) Recently, another strategy for the preparation of imidazole derivatives based on the
exploitation of the racemic α-methylbenzylamine was reported [19].
57.2 Hz) and the quartet of H-C(1') at 5.27 ppm. The product (R)-7a, obtained from the
reaction with (R)-(+)-6, showed [α]D
20 = –138.5 (c 1.00, MeOH). On the other hand, the
enantiomer (S)-7a, which was formed in the reaction with (S)-(–)-6, displayed the same
spectroscopic data and [α]D
20 = +131.5 (c 1.02, MeOH).
The 4,5-diphenyl analogues 7b were prepared by using benzil monoxime 5b. In
this case, however, the highest yield of the product was obtained when the reaction of
the imine (R)-8 with 5b was carried out in AcOH instead of MeOH, according to the
procedure described earlier [13][17]. After 24 h at room temperature, the product
formed was converted into the corresponding hydrochloride, which, after crystallization,
was neutralized by treatment with solid NaHCO3 to give the free N-oxide 7b in 75–78%
yield (Scheme 3).
Scheme 3
The successful preparation of 7a and 7b prompted us to carry out the analogous
reaction with optically active α -cyanobenzylamine (2-amino-2-phenylacetonitrile).
However, the experiment with 5a and formaldehyde under the described conditions
failed to give the desired product of type 7.
The optical purity of (R )- and (S )-7b  was tested by using (R )-(+)-(tert-
butyl)(phenyl)thiophosphonic acid ((R)-9) as a chiral solvating agent [20]. Preliminary
1H-NMR experiments with racemic 7b and equimolar amounts of (R)-9 evidenced that,
in CDCl3 at room temperature, two well separated signals of H-C(2) appeared at 9.25
and 9.10 ppm. Under similar conditions, the optically active (R)- and (S)-7b showed
only one single signal at 9.42 and 9.30 ppm, respectively. This result confirms that (R)-
6and (S)-7b are optically pure according to 1H-NMR accuracy, i.e., the conversion of 6 to
the corresponding imidazole 3-oxides 7b occurred with complete retention of the
configuration of the 1-phenylethylamine fragment.
Formula (R)-9
Freshly prepared Raney nickel has been shown to be an excellent deoxygenating
agent for imidazole 3-oxides [12][13]. Treatment of the (R)- and (S)-enantiomer of 7a
and 7b with this reagent in MeOH at room temperature led to the corresponding
imidazoles 10 within 30 min (TLC) in almost quantitative yield (Scheme 4).
Scheme 4
The optically active imidazole-2-thiones of type 11 were easily prepared by using
the sulfur-transfer reaction described in [9]. For example, the color of the red solution of
2,2,4,4-tetramethyl-3-thioxocyclobutanone (12) and (S)-7a in CHCl3 vanished after 1 h
stirring at room temperature. The colorless crystalline product (S)-11a was isolated in
84% yield (Scheme 4). The mechanism of this conversion via an intermediate 1,4,2-
oxathiazolidine, formed as an unstable [2+3] cycloadduct, was described earlier [9].
3. Conclusions. – The described results show that optically active 1-
phenylethylamine can be used for the synthesis of optically active 2-unsubstituted
imidazole 3-oxides of type 7  via condensation with formaldehyde and α -
(hydroxyimino)ketones. The reaction occurs without loss of optical purity. The
7enantiomerically pure thiophosphonic acid (R)-9 is a convenient chiral solvating agent
for the determination of the optical purity of compounds 7. Using the known protocols,
imidazole 3-oxides 7 can easily be converted into the corresponding imidazoles 10 and
imidazole-2(3H)-thiones 11. All of the described optically active imidazole derivatives
can be considered as attractive ligands in coordination chemistry and precursors of
carbenes derived from imidazole [21].
The authors thank the Polish Ministry for Science and Higher Education for a
grant (PBZ KBN 126/T09/2004) and F. Hoffmann-La Roche AG, Basel, for financial
support.
Experimental Part
1. General. M.p.: Melt-Temp. II apparatus (Aldrich); in capillary, uncorrected. IR
Spectra (KBr): NEXUS FT-IR spectrophotometer. 1H- and 13C-NMR Spectra: Tesla
BS567A (80 and 20 MHz, resp.) or Bruker AC 300 instrument (300 and 75.5 MHz,
resp.); in CDCl3, TMS as an internal standard. The multiplicity of the 
13C signals was
deduced from the DEPT spectra. MS (EI or CI): Finnigan MAT-90 or Finnigan SSQ-
700 instruments. Elemental analyses were performed in the Analytical Laboratory of the
University of Zürich.
2. Starting materials. α-(Hydroxyimino)ketones 5 were obtained according to
known protocols: butane-2,3-dione monooxime (5a) by nitrosation of butan-2-one [22a]
8and 1,2-diphenylethane-1,2-dione monooxime (5b, benzil monooxime) from dibenzoyl
and hydroxylamine hydrochloride [22b]. (R)-(+)-(tert-Butyl)(phenyl)thiophosphonic
acid ((R)-9) was obtained by resolution of the racemic mixture according to a known
protocol [20b].
3. Synthesis of Enantiomerically Pure Imidazole 3-Oxides. Method A: To a stirred
soln. of (R)- or (S)-α-methylbenzylamine ((R)- or (S)-6; 242 mg, 2.00 mmol) in MeOH
(5 ml), solid formaldehyde (63.0 g, 2.1 mmol) was added and stirring was continued
overnight. Then, the mixture was concentrated, butane-2,3-dione monooxime (5a; 258
mg, 2.56 mmol) was added, and the mixture heated to reflux for 3 h. The solvent was
removed under reduced pressure and the resulting solid was washed with acetone to
give analytically pure samples.
 3.1. (R)-1-(1-Phenylethyl)-4,5-dimethylimidazole 3-Oxide ((R)-7a). Yield: 355
mg (82%). Colorless crystals. M.p. (dec.) 224º. IR: 3059m, 2993s, 2939m, 1633m,
1602w, 1490m, 1445m, 1409m, 1346s, 1335vs, 1236m, 1198s, 1047m, 850m, 807m,
752s, 699vs, 595s, 581m. 1H-NMR: 1.82 (d, JH-H = 7.2, MeCH); 2.00, 2.18 (2s, 2 Me);
5.27 (q, JH-H = 7.0, MeCH); 7.08–7.40 (m, 5 arom. H); 8.16 (s, HC(2)). 
13C-NMR: 7.2,
9.0 (2 Me); 22.0 (MeCH); 55.7 (MeCH); 125.6, 128.4, 129.2 (5 arom. CH); 122.8
(C(2)); 121.3, 127.3, 140.1 (3 Cq). EI-MS: 216 (6, M
+.), 200 (10, [M–16]+), 105 (100),
96 (27). CI-MS (NH3): 218 (15), 217 (100, [M+1]
+), 201 (19), 105 (9). Anal. calc. for
C13H16N2O (216.29): C 72.19, H 7.46; found: C 72.24, H 7.38. [α]D
20 = –138.5 (c 1.00;
MeOH).
3.2. (S)-1-(1-Phenylethyl)-4,5-dimethylimidazole 3-Oxide ((S)-7a). Yield: 380 mg
(88%). Colorless crystals. M.p. (dec.) 230º. IR: 3060m, 2982s, 2939m, 1633m, 1602w,
91490m, 1445m, 1408m, 1345s, 1334vs, 1236m, 1197s, 1047m, 849m, 807m, 752s,
700vs, 595s, 580m. CI-MS (NH3): 218 (15), 217 (100, [M+1]
+), 201 (8), 105 (100).
[α]D
20 = + 131.5 (c 1.02; MeOH).
Method B. To a stirred soln. of (R)- or (S)-6 (242 mg, 2.00 mmol) in MeOH (5
ml), solid formaldehyde (63.0 g, 2.1 mmol) was added and stirring was continued
overnight. The solvent was evaporated, the resulting oil and 1,2-diphenylethane-1,2-
dione monooxime (5b; 304 mg, 2.48 mmol) in AcOH (10 ml) was stirred overnight at
r.t. Then, HCl gas was bubbled through the soln. for 1.5 h. The solvent was evaporated,
the obtained oil was washed with Et2O, the colorless hydrochloride was filtered and
dried in vacuo. The crude hydrochloride was dissolved in MeOH (30 ml), solid
NaHCO3 (1.0 g) was added, and stirring was continued for 1 h. The inorganic salts were
filtered off, the solvent was evaporated, the solid residue washed with CHCl3/MeOH
(2:1) and then triturated with acetone. The colorless crystals obtained were analytically
pure.
3.3. (R)-1-(1-Phenylethyl)-4,5-diphenylimidazole 3-Oxide ((R)-7b). Yield: 510 mg
(75%). Colorless crystals. M.p. (dec.) 217º. IR: 3046s, 2990m, 2964m, 2949m, 1636m,
1602m, 1585m, 1497m, 1444m, 1340s, 1237m, 767m, 761m, 703s. [α]D
20 = +30.0 (c
1.00; MeOH).
3.4. (S)-1-(1-Phenylethyl)-4,5-diphenylimidazole 3-Oxide ((S)-7b). Yield: 530 mg
(78%). Colorless crystals. M.p. (dec.) 218º. IR: 3046s, 2990m, 2961m, 2949m, 1636m,
1602m, 1584m, 1497m, 1444m, 1340s, 1236m, 767m, 760m, 703s. 1H-NMR: 1.78 (d,
JH-H = 7.1, MeCH); 5.24 (q, JH-H = 7.1, MeCH); 7.03–7.60 (m, 15 arom. H); 8.08 (s,
HC(2)). 13C-NMR: 21.8 (MeCH); 55.5 (MeCH); 124.1, 125.9, 127.9, 128.5, 129.0,
129.1, 129.5, 129.6, 130.9 (15 arom. CH, C(2)); 126.8, 127.1, 127.6, 128.3, 139.7 (5
10
Cq). CI-MS (isobutan): 342 (24), 341 (100, [M+1]
+), 325 (20). Anal. calc. for
C23H20N2O (340.43): C 81.15, H 5.92, N 8.23; found: C 80.97, H 6.02, N 8.25. [α]D
20 =
–27.0 (c 0.98; MeOH).
4. Deoxygenation of Enantiomerically Pure Imidazole 3-Oxides. To a soln. of  the
corresponding (R)- or (S)-imidazole 3-oxide 7  (1.0 mmol) in MeOH (5 ml), a
suspension of freshly prepared Raney nickel in MeOH was added in small portions.
When the starting N-oxide 7 was completely reduced (TLC), the mixture was filtered
and the filtrate was concentrated under reduced pressure. Crude products were purified
by recrystallization from hexane/CH2Cl2.
4.1. (R)-1-(1-Phenylethyl)-4,5-dimethylimidazole ((R)-10a). Yield: 153 mg (77%).
Colorless crystals. M.p. (dec.) 179º (hexane/CH2Cl2). IR: 3103m , 3083m , 3062m ,
3029m, 2988m, 2980m, 2925m, 2865m, 1641m, 1599m, 1493m, 1482m, 1445m, 1389m,
1344m, 1236s, 755m, 699s. 1H-NMR: 1.83 (d, JH-H = 7.1, MeCH); 1.92, 2.15 (2s, 2 Me);
5.17 (q, JH-H = 7.1, MeCH); 7.00–7.38 (m, 5 arom. H); 7.56 (s, HC(2)). 
13C-NMR: 8.6,
12.6 (2 Me); 22.3 (MeCH); 54.8 (MeCH); 125.5, 127.5, 128.7 (5 arom. CH); 122.4,
134.2, 142.0 (3 Cq); 132.6 (C(2)). CI-MS (NH3): 202 (15), 201 (100, [M+1]
+), 200 (10),
105 (8). Anal. calc. for C13H16N2 (200.29): C 77.96, H 8.05, N 13.99; found: C 77.94, H
8.12, N 14.01. [α]D
20 = –43.0 (c 1.10; MeOH).
4.2. (S)-1-(1-Phenylethyl)-4,5-dimethylimidazole ((S)-10a). Yield: 162 mg (82%).
Colorless crystals. M.p. (dec.) 178º (hexane/CH2Cl2). IR: 3103m , 3083m , 3062m ,
3030m, 2988m, 2980m, 2925m, 2865m, 1646m, 1599m, 1493m, 1482m, 1445m, 1389m,
1344m, 1236s, 755m, 699s. CI-MS (NH3): 202 (15), 201 (100, [M+1]
+), 200 (6), 105
(3). [α]D
20 = +33.3 (c 1.00; MeOH).
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4.3. (R)-1-(1-Phenylethyl)-4,5-diphenylimidazole ((R)-10b). Yield: 227 mg
(73%). Colorless crystals. M.p. (dec. )  180º (hexane/CH2Cl2). IR: 3090m , 3063m ,
3049m, 3032m, 2983m, 2945m, 1634s, 1601m, 1505m, 1485m, 1474m, 1454m, 1442m,
1374m, 768m, 695s. [α]D
20 = +83.0 (c 1.00; MeOH).
4.4. (S)-1-(1-Phenylethyl)-4,5-diphenylimidazole ((S)-10b). Yield: 255 mg (82%).
Colorless crystals. M.p. (dec.) 176º (hexane/CH2Cl2). IR: 3090m , 3063m , 3049m ,
3032m, 2984m, 2946m, 1633s, 1601m, 1505m, 1484m, 1473m, 1454m, 1442m, 1375m,
768m, 695s. 1H-NMR: 1.81 (d, JH-H = 7.1, M eCH); 5.11 (q, JH-H = 7.1, MeCH);
6.95–7.50 (m, 15 arom. H); 7.76 (s, HC(2)). 13C-NMR: 22.4 (MeCH); 54.5 (MeCH);
125.8, 126.2, 126.4, 127.7, 128.1, 128.7, 128.8, 131.1, 134.4 (15 arom. CH, C(2));
127.3, 128.3, 130.9, 138.1, 141.8 (5 Cq). CI-MS (isobutan): 326 (22), 325 (100,
[M+1]+), 324 (70, M+.). Anal. calc. for C23H20N2 (324.43): C 85.15, H  6.21, N 8.63;
found: C 84.95, H 6.17, N 8.54. [α]D
20 = –80 (c 0.60, MeOH)
5. Transformations of Enantiomerically Pure Imidazole 3-Oxides into Imidazole-
2(3H )-thiones. To a cooled CHCl3 soln. (water bath) of 2,2,4,4-tetramethyl-3-
thioxocyclobutanone (12; 1 mmol), the respective imidazole 3-oxide 7 (1 mmol) was
added in small portions and the mixture was stirred for ca. 1 h until the characteristic
red color of the soln. vanished. After concentration under reduced pressure, the mixture
was washed with pentane, and the obtained crude solid was recrystallized from MeOH
or from petroleum ether/Et2O.
5.1. (R)-1,3-Dihydro-4,5-dimethyl-1-(1-phenylethyl)imidazole-2-thione ((R)-11a).
Yield: 190 mg (82%). Colorless crystals. M.p. 124–126° (petroleum ether/Et2O). IR:
3159m, 3086s, 2979m, 2926s, 2718m, 1655m, 1605m, 1496s, 1448s, 1415s, 1374s,
1332m, 1239m, 1028m, 750m, 700s. [α]D
20 = +176.0 (c 1.00; CH2Cl2).
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5.2. (S)-1,3-Dihydro-4,5-dimethyl-1-(1-phenylethyl)imidazole-2-thione ((S)-11a).
Yield: 194 mg (84%). Colorless crystals. M.p. 126–128° (petroleum ether/Et2O). IR:
3162m, 3086s, 2978m, 2926s, 2718m, 1656m, 1605m, 1496s, 1448s, 1415s, 1374s,
1332m, 1239m, 1028m, 751m, 700s. 1H-NMR: 1.67, 2.05 (2s, 2 Me); 1.81 (d, JH-H = 7.1,
MeCH); 6.61 (q, JH-H= 7.1, MeCH); 7.27–7.34 (m, 5 arom. H); 11.69 (br. s, NH). 
13C-
NMR: 8.7, 9.8 (2 Me); 17.1 (MeCH); 53.3 (MeCH); 121.0, 121.3 (2 MeCq); 126.5,
127.3, 128.5 (5 arom. CH); 139.9 (arom. Cq); 158.5 (C=S). CI-MS (isobutan): 233 (100,
[M+1]+), 232 (12). Anal. calc. for C13H16N2S (232.35): C 67.20, H 6.94, N 12.06, S
13.8; found: C 67.05, H 7.05, N 12.17, S 13.55. [α]D
20 = –170.0 (c 0.90; CH2Cl2).
5.3. (R)-1,3-Dihydro-4,5-diphenyl-1-(1-phenylethyl)imidazole-2-thione ((R)-11b).
Yield: 275 mg (77%). Colorless crystals. M.p. 282–284° (MeOH). IR: 3088m, 3061m,
2982m, 2936m, 2726m, 1630m, 1603m, 1491s, 1477m, 1446m, 1406m, 1374m, 1345m,
1254m, 761m, 687s. 1H-NMR: 1.61 (d, JH-H = 7.1, MeCH); 7.05–7.35 (m, 15 arom. H,
MeCH); 12.15 (s, NH). 13C-NMR: 17.4 (MeCH); 54.4 (MeCH); 126.2, 127.9, 128.7,
140.1 (5 Cq); 126.4, 126.9, 127.2, 127.7, 128.1, 128.2, 128.5, 129.0, 132.0 (15 arom.
CH); 160.9 (C=S). CI-MS (isobutan): 358 (24), 357 (100, [M+1]+), 356 (21). Anal. calc.
for C23H20N2S (356.49): C 77.49, H 5.65, N 7.86, S 8.99; found: C 77.28, H 5.73, N
7.74, S 8.78. [α]D
20 = +74.7 (c 1.1; CH2Cl2).
5.4. (S)-1,3-Dihydro-4,5-diphenyl-1-(1-phenylethyl)imidazole-2-thione ((S)-11b).
Yield: 268 mg (75%). Colorless crystals. M.p. 276–278° (MeOH). IR: 3089m, 3061m,
2983m, 2938m, 2729m, 1632m, 1603m, 1491s, 1479m, 1446m, 1407m, 1376m, 1344m,
1254m, 759m, 697s.  [α]D
20 = –58.0 (c 1.00; CH2Cl2).
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